´ÙÀ̺¸³Ø½º¿¬°í(Ä®½ÃÆ÷Æ®¸®¿Ã) 30g Daivonex Ointment 30g
Àü¹®ÀǾàǰ | ±Þ¿©
¼öÀÔÀǾàǰ
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
Àü¹®
¾à°£Åõ¸íÇÑ ¹é»ö-¹ÌȲ»öÀÇ ¿¬°íÁ¦ÀÌ´Ù.
Á¦Á¶È¸»ç
·¹¿ÀÆÄ¸¶(À¯)
ÆÇ¸Åȸ»ç
·¹¿ÀÆÄ¸¶(À¯)
Çã°¡Á¤º¸
Á¤»ó
(1993.02.27)
BIT ¾àÈ¿ºÐ·ù
°Ç¼±Ä¡·áÁ¦(Drugs for Psoriasis)
º¹ÁöºÎºÐ·ù
269[±âŸÀÇ ¿ÜÇÇ¿ë¾à ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
626700011 \10,560 ¿ø/30g/°³(2022.07.15) (ÇöÀç¾à°¡) \13,788 ¿ø/30g/°³(2022.01.01) (º¯°æÀü¾à°¡)
ATCÄÚµå
Calcipotriol / D05AX02
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
¸¶Å©·Î°ñ-(2)-½ºÅ׾Ƹ±¿¡ÅÚ ,
¹é»ö¹Ù¼¿¸° ,
¾ËÆÄÅäÄÚÆä·Ñ ,
¿¡µ¥Æ®»ê³ªÆ®·ý ,
À¯µ¿ ÆÄ¶óÇÉ ,
Àλê¼ö¼Ò³ªÆ®·ýÀ̼öȹ° ,
Á¤Á¦¼ö ,
ÇÁ·ÎÇÊ·»±Û¸®ÄÝ
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
626700011
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\10,560 ¿ø/30g/°³(2022.07.15) (ÇöÀç¾à°¡)
\13,788 ¿ø/30g/°³(2022.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
¾à°£Åõ¸íÇÑ ¹é»ö-¹ÌȲ»öÀÇ ¿¬°íÁ¦ÀÌ´Ù. [Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
Á¦Á¶¿øÀÇ Æ÷Àå´ÜÀ§
Æ÷À塤ÄÚµå´ÜÀ§
¾àǰ±Ô°Ý
´ÜÀ§
Æ÷ÀåÇüÅÂ
´ëÇ¥ÄÚµå
Ç¥ÁØÄÚµå
ºñ°í
30±×·¥
1 °³
Æ©ºê
8806267000102
8806267000119
ÁÖ¼ººÐÄÚµå
121530COM
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
Çã°¡»çÇ× ¿ø¹®Á¶È¸
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
°Ç¼±(°æÁõ ¹× ÁßµîÁõ)
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ
ȯºÎ¿¡ 1ÀÏ 1-2ȸ(¾ÆÄ§, Àú³á) ¹Ù¸¥´Ù. ÃÖ´ë È¿°ú¸¦ À§Çؼ´Â 1ÀÏ 2ȸ »ç¿ëÇØ¾ß ÇÑ´Ù. 1ÁÖ¿¡ 100g(1ÀÏ ¾à 15gÀÌ»ó)À» ÃʰúÇÏ¿© »ç¿ëÇÏÁö ¾Ê´Â´Ù. Ä®½ÃÆ÷Æ®¸®¿ÃÀ» ÇÔÀ¯ÇÏ´Â ´Ù¸¥ ¾à°ú ÇÔ²² »ç¿ëÇÒ °æ¿ì, ÀÌ ¾àÀ» Æ÷ÇÔÇØ¼ ¸ðµç Ä®½ÃÆ÷Æ®¸®¿Ã ÇÔÀ¯ Á¦Á¦ÀÇ 1ÁÖÀÏ ÃÑÅõ¿©·®ÀÌ Ä®½ÃÆ÷Æ®¸®¿Ã 5mgÀ» ÃʰúÇØ¼´Â ¾È µÈ´Ù.
±Ý±â
1) ÀÌ ¾à ¹× ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõ ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ
2) °íÄ®½·Ç÷Áõ µî Ä®½·´ë»ç Àå¾Ö ȯÀÚ
3) ºñŸ¹Î D µ¶¼ºÀ» ³ªÅ¸³»´Â ȯÀÚ
½ÅÁßÅõ¿©
ÀÌ ¾àÀº ÇÁ·ÎÇÊ·»±Û¸®ÄÝÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
ÀÌ»ó¹ÝÀÀ
ÀÌ»ó¹ÝÀÀÀÇ ºóµµ´Â ÀÓ»ó½ÃÇè ¹× ÀÚ¹ßÀû º¸°í¿¡¼ ³ª¿Â µ¥ÀÌÅ͸¦ Á¾ÇÕ ºÐ¼®ÇÏ¿© Æò°¡µÇ¾ú´Ù.
°¡Àå ºó¹øÇÏ°Ô º¸°íµÈ ÀÌ»ó¹ÝÀÀÀº °¡·Á¿ò, ÇǺΠÀÚ±Ø, È«¹ÝÀ̾ú´Ù.
Àü½Å ¹ÝÀÀ(°íÄ®½·Ç÷Áõ ¹× °íÄ®½·´¢)ÀÌ º¸°íµÈ ¹Ù ÀÖ´Ù. °ú·® Åõ¿©½Ã ÀÌ·¯ÇÑ ¹ÝÀÀÀÌ ¹ß»ýÇÒ À§ÇèÀÌ Áõ°¡ÇÑ´Ù.
ÀÌ»ó¹ÝÀÀÀº MedDRA SOC¿¡ ÀÇÇØ ¿°ÅµÇ¸ç °³º°ÀûÀÎ ÀÌ»ó¹ÝÀÀÀº ºóµµ°¡ ³ôÀº ¼ø¼´ë·Î ³ª¿µÈ´Ù. µ¿ÀÏÇÑ ºóµµ ³»¿¡¼´Â ÁßÁõµµ°¡ °¨¼ÒÇÏ´Â ¼ø¼´ë·Î ³ª¿µÈ´Ù.
¸Å¿ì ÈçÇÏ°Ô (¡Ã1/10), ÈçÇÏ°Ô (¡Ã1/100¿¡¼ <1/10)
ÈçÇÏÁö ¾Ê°Ô (¡Ã1/1,000¿¡¼ <1/100), µå¹°°Ô (¡Ã1/10,000¿¡¼ <1/1,000), ¸Å¿ì µå¹°°Ô (<1/10,000)
ºóµµ
ÀÌ»ó¹ÝÀÀ
°¨¿°
ÈçÇÏÁö ¾Ê°Ô (¡Ã1/1,000¿¡¼ <1/100)
¸ð³¶¿°
¸é¿ª°è ÀÌ»ó
µå¹°°Ô (¡Ã1/10,000¿¡¼ <1/1,000)
°ú¹ÎÁõ
´ë»ç ¹× ¿µ¾ç ÀÌ»ó
µå¹°°Ô (¡Ã1/10,000¿¡¼ <1/1,000)
°íÄ®½·Ç÷Áõ
ÇǺΠ¹× ÇÇÇÏÁ¶Á÷ ÀÌ»ó
ÈçÇÏ°Ô (¡Ã1/100¿¡¼ <1/10)
°Ç¼±ÀÇ ¾ÇÈ, ÇǺο°, È«¹Ý, ¹ÚÇÇ,
ÀÛ¿°¨, ÇǺΠÀÚ±Ø, °¡·Á¿ò
ÈçÇÏÁö ¾Ê°Ô (¡Ã1/1,000¿¡¼ <1/100)
¹ßÁø*, ÇǺΠ°ÇÁ¶
µå¹°°Ô (¡Ã1/10,000¿¡¼ <1/1,000)
±¤°ú¹ÎÁõ, ÇǺΠºÎÁ¾, µÎµå·¯±â,
Áö·ç¼º ÇǺο°
½ÅÀå ¹× ¿ä°ü ÀÌ»ó
µå¹°°Ô (¡Ã1/10,000¿¡¼ <1/1,000)
°íÄ®½·´¢
ÀϹÝÀû ÀÌ»ó ¹× Åõ¿©ºÎÀ§ »óÅÂ
ÈçÇÏ°Ô (¡Ã1/100¿¡¼ <1/10)
Åõ¿©ºÎÀ§ ÅëÁõ
ÈçÇÏÁö ¾Ê°Ô (¡Ã1/1,000¿¡¼ <1/100)
Åõ¿©ºÎÀ§ »ö¼ÒÄ§Âø º¯È
* È«¹Ý¼º ¹ßÁø, ¹Ý±¸Áø¹ßÁø, È«¿ª¸ð¾ç¹ßÁø, ±¸Áø¹ßÁø, ³óÆ÷¹ßÁø°ú °°Àº ´Ù¾çÇÑ À¯ÇüÀÇ ¹ßÁø ¹ÝÀÀÀÌ º¸°íµÇ¾ú´Ù.
»óÈ£ÀÛ¿ë
ÀÌ ¾à¿¡ ´ëÇÑ »óÈ£ÀÛ¿ëÀº ¿¬±¸µÇÁö ¾Ê¾Ò´Ù.
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Cµî±Þ
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Á¦Çüº° º¹¾àÁöµµ
[¿¬°í]
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
Mechanism of Action
Calcipotriol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The precise mechanism of calcipotriol in remitting psoriasis is not well-understood. However, it has been shown to have comparable affinity with calcitriol for the Vitamin D receptor, while being less than 1% as active as the calcitriol in regulating calcium metabolism. The Vitamin D receptor (VDR) belongs to the steroid/thyroid receptor superfamily, and is found on the cells of many different tissues including the thyroid, bone, kindney, and T cells of the immune system. T cells are known to play a role in psoriasis, and it is thought that the binding of calcipotriol to the VDR modulates the T cells gene transcription of cell differentiation and proliferation related genes.
Pharmacology
Calcipotriol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Calcipotriene is a synthetic analog of vitamin D. In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D3 (cholecalciferol) in the skin.
Absorption
Calcipotriol¿¡ ´ëÇÑ Absorption Á¤º¸ Clinical studies with radiolabeled ointment indicate that approximately 6% (+3%, SD) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques or 5% (+2.6%, SO) when applied to normal skin.
Pharmacokinetics
CalcipotriolÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
ÀÛ¿ë¹ßÇö½Ã°£ : 1ÁÖ
ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : 8ÁÖ
ÀÛ¿ëÁö¼Ó½Ã°£ : ¹Ýº¹ Àû¿ë : 4ÁÖ
Èí¼ö : ±¹¼Ò Àû¿ë : Á¤»ó ÇǺο¡ Àû¿ë½Ã ¾à 5%, °Ç¼± plaque¿¡ Àû¿ë½Ã ¾à 6%°¡ Àü½ÅÀûÀ¸·Î Èí¼öµÈ´Ù.
´ë»ç : Àü½ÅÀûÀ¸·Î Èí¼öµÈ ¾à¹°Àº Àû¿ë 24½Ã°£ À̳»¿¡ ÁÖ·Î °£¿¡¼ ºñȰ¼ºÇü ´ë»çü·Î ´ë»çµÈ´Ù.
Biotransformation
Calcipotriol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic. Calcipotriene metabolism following systemic uptake is rapid, and occurs via a similar pathway to the natural hormone. The primary metabolites are much less potent than the parent compound.
Toxicity
Calcipotriol¿¡ ´ëÇÑ Toxicity Á¤º¸ Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of calcipotriene.
Drug Interactions
Calcipotriol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Drug Target
[Drug Target]
Description
Calcipotriol¿¡ ´ëÇÑ Description Á¤º¸ Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.
Dosage Form
Calcipotriol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Cream TopicalOintment TopicalShampoo Topical
Drug Category
Calcipotriol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antipsoriatic AgentsDermatologic AgentsVitamin D3 Receptor inhibitor
Smiles String Canonical
Calcipotriol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C=CC(O)C1CC1)C1CCC2C1(C)CCCC2=CC=C1CC(O)CC(O)C1=C
Smiles String Isomeric
Calcipotriol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2[C@@]1(C)CCC\C2=C\C=C1\C[C@H](O)C[C@@H](O)C1=C
InChI Identifier
Calcipotriol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7-,21-10-
Chemical IUPAC Name
Calcipotriol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2022-08-02
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ